These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 31733406)

  • 1. Challenges in the Regulation of High-Cost Treatments: An Overview From Brazil.
    Pereira LC; Sturzenegger DVR; Ortiz J; Ayad NME; Cortopassi WA; Safatle LP; Khuri N
    Value Health Reg Issues; 2019 Dec; 20():191-195. PubMed ID: 31733406
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Problems in the regulatory policy of the drug market.
    Miziara NM; Coutinho DR
    Rev Saude Publica; 2015; 49():35. PubMed ID: 26083945
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative Approaches to Drug Pricing.
    Kang SY; Bai G; DiStefano MJ; Socal MP; Yehia F; Anderson GF
    Annu Rev Public Health; 2020 Apr; 41():499-512. PubMed ID: 31874070
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pricing and reimbursement of pharmaceuticals in the Czech Republic and Sweden.
    Davidova J; Praznovcova L; Lundborg CS
    Pharm World Sci; 2008 Jan; 30(1):57-64. PubMed ID: 17588212
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [International reference prices and cost minimization analysis for the regulation of medicine prices in Colombia].
    Vacca C; Acosta A; Rodriguez I
    Value Health; 2011; 14(5 Suppl 1):S16-9. PubMed ID: 21839891
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Government commitment and regulation of prescription drugs.
    Frank RG
    Health Aff (Millwood); 2003; 22(3):46-8. PubMed ID: 12757271
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Medicare Drug-Price Negotiation - Why Now . . . and How.
    Frank RG; Nichols LM
    N Engl J Med; 2019 Oct; 381(15):1404-1406. PubMed ID: 31483959
    [No Abstract]   [Full Text] [Related]  

  • 8. Pharmaceutical cost control in Canada: does it work?
    Menon D
    Health Aff (Millwood); 2001; 20(3):92-103. PubMed ID: 11585186
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The High Cost of Prescription Drugs in the United States: Origins and Prospects for Reform.
    Kesselheim AS; Avorn J; Sarpatwari A
    JAMA; 2016 Aug 23-30; 316(8):858-71. PubMed ID: 27552619
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Affordability Boards - The States' New Fix for Drug Pricing.
    Sklar T; Robertson C
    N Engl J Med; 2019 Oct; 381(14):1301-1303. PubMed ID: 31577871
    [No Abstract]   [Full Text] [Related]  

  • 11. Initiatives to challenge patent barriers and their relationship with the price of medicines procured by the Brazilian Unified National Health System.
    Scopel CT; Chaves GC
    Cad Saude Publica; 2016 Dec; 32(11):e00113815. PubMed ID: 27925025
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmaceutical policy in the Netherlands: from price regulation towards managed competition.
    Boonen LH; van der Geest SA; Schut FT; Varkevisser M
    Adv Health Econ Health Serv Res; 2010; 22():53-76. PubMed ID: 20575228
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Retail prices of essential drugs in Brazil: an international comparison.
    Nóbrega Ode T; Marques AR; de Araújo AC; Karnikowski MG; Naves Jde O; Silver LD
    Rev Panam Salud Publica; 2007 Aug; 22(2):118-23. PubMed ID: 17976278
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Canada's Amendment to Patented Drug Price Regulation: A Prescription for Global Drug Cost Control?
    Humphries B; Xie F
    JAMA; 2019 Apr; 321(16):1565-1566. PubMed ID: 30924840
    [No Abstract]   [Full Text] [Related]  

  • 15. To Dent Soaring Drug Costs, States Turn to 'Price-Gouging' Laws.
    Kirkner RM
    Manag Care; 2017 Sep; 26(9):8-9. PubMed ID: 29068301
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Can price controls reduce pharmaceutical expenses? A case study of antibacterial expenditures in 12 Chinese hospitals from 1996 to 2005.
    Han S; Liang H; Su W; Xue Y; Shi L
    Int J Health Serv; 2013; 43(1):91-103. PubMed ID: 23527456
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Determinants of orphan drugs prices in France: a regression analysis.
    Korchagina D; Millier A; Vataire AL; Aballea S; Falissard B; Toumi M
    Orphanet J Rare Dis; 2017 Apr; 12(1):75. PubMed ID: 28427466
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reimbursed Price of Orphan Drugs: Current Strategies and Potential Improvements.
    Mincarone P; Leo CG; Sabina S; Sarriá-Santamera A; Taruscio D; Serrano-Aguilar PG; Kanavos P
    Public Health Genomics; 2017; 20(1):1-8. PubMed ID: 28359063
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The pharmaceutical industry--prices and progress.
    Scherer FM
    N Engl J Med; 2004 Aug; 351(9):927-32. PubMed ID: 15329432
    [No Abstract]   [Full Text] [Related]  

  • 20. [Consequences of the judicialization of health policies: the cost of medicines for mucopolysaccharidosis].
    Diniz D; Medeiros M; Schwartz IV
    Cad Saude Publica; 2012 Mar; 28(3):479-89. PubMed ID: 22415180
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.